

FEBRUARY

Date	Headline and Source	Link	Summary
1 st February	Budget 2024 expectations: R&D, infrastructure, and accessibility top healthcare sector s wish list Business Today, February 01, 2024	Budget 2024 expectations: R&D, infrastructure, and accessibility top healthcare sector s wish list	To further support research to develop innovative pharma product, the concessional tax rates under Section 115BAB of Income Tax Act, 1961 should be extended to companies solely engaged in R&D of pharma as well, beyond those related to manufactured articles. We also hope for the elimination of import duties on lifesaving drugs, recognizing that individuals should not bear substantial taxes during health crises, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI).
1 st February	Battle brewing: Roche questions Zydus on clinical trials for its breast cancer drug Perjeta (Pertuzumab) ET Health World, February 01, 2024	Battle brewing: Roche questions Zydus on clinical trials for its breast cancer drug Perjeta (Pertuzumab)	Roche, the world's top seller of oncology drugs, has raised red flags against the clinical trials conducted by Indian drug maker Zydus Lifesciences on Perjeta (pertuzumab), its popular breast cancer treatment. The Swiss drug maker has alleged that 500 vials of the drug were sourced from questionable channels for clinical trials in India.
1 st February	Pfizer and Glenmark partner to introduce novel atopic dermatitis treatment in India Business Today, February 01, 2024	Pfizer and Glenmark partner to introduce novel atopic dermatitis treatment in India	Pharma majors Pfizer and Glenmark Pharmaceuticals Ltd on Wednesday announced to have collaborated to introduce abrocitinib, a novel oral treatment for moderate to severe atopic dermatitis, in India. Atopic dermatitis is a debilitating form of chronic skin inflammation characterised by severe itching and skin lesions.
1 st February	P&G Hygiene and Health Care Q2 Results: Profit up 10.3% at Rs 229 cr The Economic Times, February 01, 2024	P&G Hygiene and Health Care Q2 Results: Profit up 10.3% at Rs 229 cr	Procter & Gamble Hygiene and Health Care Ltd on Wednesday reported a growth of 10 32 per cent in profit after tax at Rs 228 90 crore in the second quarter ended December 2023 largely led by productivity, and moderating cost inflation.
2 nd February	Budget allocates Rs 90,658 crore to health ministry, reflecting a 12.5% increase Money Control, February 02, 2024	Budget allocates Rs 90,658 crore to health ministry, reflecting a 12.5% increase	The emphasis on leveraging existing hospital infrastructure for establishing new medical colleges is a strategic move that aligns with the need for a robust healthcare workforce, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), on the budget.
2 nd February	Bracing for 10 million AMR deaths per year by 2050	Bracing for 10 million AMR deaths per year by 2050	Antibiotic resistance is intrinsically linked to animal and human consumption patterns, partly driven by inappropriate use of

	BioSpectrum India, February 02, 2024		antibiotics. In turn, the emergence of antibiotic resistance fuels changes in consumption patterns, as more costly broad-spectrum antibiotics become required to manage even common conditions.
2 nd February	Budget 2024: Top reactions from healthcare industry leaders-Who said what on Nirmala Sitharaman's announcements The Financial Express, February 02, 2024	Budget 2024: Top reactions from healthcare industry leaders-Who said what on Nirmala Sitharaman's announcements	OPPI and its members wholeheartedly support any balanced & equitable steps of the government which are in line with the first develop India spirit. While we appreciate the positive strides taken in the Union Budget 2024 towards the healthcare and pharmaceutical sector, we were also hoping that a nuanced approach to reduce duty/tax burdens on innovative & lifesaving drugs, addressing regulatory challenges and facilitating ease of doing business could have been outlined.
2 nd February	Industry lauds Union Budget's focus on Women s Health Express Pharma, February 02, 2024	Industry lauds Union Budget's focus on Women s Health	OPPI commends the Government's approach towards the healthcare and pharmaceutical sector in the Union Budget 2024. The emphasis on leveraging existing hospital infrastructure for establishing new medical colleges is a strategic move that aligns with the need for a robust healthcare workforce.
2 nd February	Healthcare sector seeks budget boost for R&D, infrastructure Medical Buyer, February 02, 2024	Healthcare sector seeks budget boost for R&D, infrastructure	We also hope for the elimination of import duties on lifesaving drugs, recognizing that individuals should not bear substantial taxes during health crises, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI).
2 nd February	Glenmark partners with Pfizer to launch drug for atopic dermatitis treatment in India BioSpectrum India, February 02, 2024	Glenmark partners with Pfizer to launch drug for atopic dermatitis treatment in India	Glenmark and Pfizer will comarket abrocitinib in India under the brand names JABRYUS and CIBINQO, respectively American pharmaceutical giant Pfizer and Mumbai-based Glenmark Pharmaceuticals have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate to severe atopic dermatitis (AD), in India.
2 nd February	Interim Budget: Over 3 mn ASHA, anganwadi workers now in Ayushman Bharat Business Standard, February 02, 2024	Interim Budget: Over 3 mn ASHA, anganwadi workers now in Ayushman Bharat	Currently, MSD Pharmaceuticals Gardasil (Rs 3,927 per dose) and Serum Institute of India's (SII) Cervavac (Rs 2,000) is available in the private market. SII confirmed that it is not supplying the vaccine to the Centre yet. Reacting to the Interim Budget, SII CEO Adar Poonawalla tweeted: I applaud the Indian government s announcement to vaccinate girls aged 9-14 against cervical cancer.

2 nd February	Volumes soar at Pfizer Ltd counter Business Standard, February 02, 2024	Volumes soar at Pfizer Ltd counter	Pfizer Ltd recorded volume of 2.03 lakh shares by 14:14 IST on NSE, a 12.3 times surge over two-week average daily volume of 16518 shares India Cements Ltd, Indus Towers Ltd, Westlife Foodworld Ltd, Motherson Sumi Wiring India Ltd are among the other stocks to see a surge in volumes on NSE today, 01 February 2024.
2 nd February	Bayer CropScience Q3 results: Profit falls 31% to Rs 93.1 cr on soft demand Business Standard, February 02, 2024	Bayer CropScience Q3 results: Profit falls 31% to Rs 93.1 cr on soft demand	Bayer CropScience, the Indian unit of German drug and pesticide maker Bayer AG, reported a 31% fall in quarterly profit on Thursday, hurt by sluggish demand for its crop-protection products. The company's profit fell to 931 million rupees (\$11.2 million) during the three months ended Dec. 31 from 1.35 billion rupees a year earlier.
2 nd February	Interim Budget Reaction: Bayer CropScience India Infoline, February 02, 2024	Interim Budget Reaction: Bayer CropScience	The Finance Minister's announcement, identifying women and farmers as key focus groups for powering India's growth, has set the stage for policies that can substantially boost development in rural areas. I am also happy to see the government's continued push to improve farmer incomes.
2 nd February	Boehringer Ingelheim India Earns Top Employer 2024 Accolade for Second Consecutive Year The Week, February 02, 2024	Boehringer Ingelheim India Earns Top Employer 2024 Accolade for Second Consecutive Year	Boehringer Ingelheim India has been recognised as a Top Employer 2024 for the second consecutive year. The certification was awarded by the Top Employers Institute, an independent global authority that recognises excellence in people practices & culture.
3 rd February	Industry responds to Interim Budget 2024-25: Highs & Lows! BioSpectrum India, February 03, 2024	Industry responds to Interim Budget 2024-25: Highs & Lows!	Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) While we appreciate the positive strides taken in the Union Budget 2024 towards the healthcare and pharmaceutical sector, we were also hoping that a nuanced approach to reduce duty/tax burdens on innovative & lifesaving drugs, addressing regulatory challenges and facilitating ease of doing business could have been outlined.
3 rd February	Sanofi India Ltd spurts 1.34%, up for five straight sessions Business Standard, February 03, 2024	Sanofi India Ltd spurts 1.34%, up for five straight sessions	Sanofi India Ltd is quoting at Rs 8906, up 1.34% on the day as on 12:44 IST on the NSE. The stock is up 66.36% in last one year as compared to a 22.87% gain in NIFTY and a 47.62% gain in the Nifty Pharma. Sanofi India Ltd rose for a fifth straight session today.
3 rd February	Transformations In Clinical Research for Better Patient Outcomes	Transformations In Clinical Research for Better Patient Outcomes	Eminent figures in the clinical research field, such as Dr. PP Bapsy, Dr. Pratima Murthy, Dr. Raches Ella, Dr. Venkat Raman Kola, Mr. A K Pradhan (ExJoint Drugs Controller, India

	Deccan Chronicle, February 03, 2024		CDSCO), and Mr. Navneet Pratap Singh (Deputy Drugs Controller, India CDSCO), attended to discuss the latest advancements, challenges, and opportunities. Representatives from leading companies like Sun Pharma, Dr. Reddy's, Zydus, Pfizer, GSK, Johnson & Johnson, Sanofi, Novo Nordisk, AstraZeneca, Novartis, IQVIA, Syneos, Fortrea, ICON, Syngene, and more shared insights.
3 rd February	Swiss healthcare company Roche inaugurates its new campus for its Digital Centre of Excellence in Pune Punekar News, February 03, 2024	Swiss healthcare company Roche inaugurates its new campus for its Digital Centre of Excellence in Pune	Roche announces the official inauguration of its Digital Centre of Excellence in Pune, India, marking a significant milestone in its history in India. This strategic presence in Pune reflects Roche's commitment to becoming a centre for digital talent and thought leadership.
3 rd February	Indian Pharma Inc hails Budget 2024 pro-development stance ET Health World, February 03, 2024	Indian Pharma Inc hails Budget 2024 pro-development stance	This forward-looking approach will not only benefit the nation's citizens but also strengthen India's position on the global stage as a proactive and innovative player in healthcare. Shweta Rai, Director, Bayer Zydus Pharma Private Limited, Country Division Head, Bayer Pharmaceuticals Business, South Asia, said, The interim Budget 2024 has some notable announcements highlight the government's aim to prioritise women's health in the country, which is commendable.
3 rd February	Nobel Laureate Prof Meldal Calls On Dr Jitendra, Discusses Collaboration In Pharmaceuticals Daily Excelsior, February 03, 2024	Nobel Laureate Prof Meldal Calls On Dr Jitendra, Discusses Collaboration In Pharmaceuticals	Hailing from Denmark, which is the home to one of the world's biggest Insulin producing houses called Novo Nordisk, the Nobel Laureate spent considerable time discussing Insulin and Diabetes management with Dr Jitendra Singh who also happens to be a nationally known Diabetologist.
4 th February	Swiss healthcare company Roche inaugurates its new campus Business News This Week, February 04, 2024	Swiss healthcare company Roche inaugurates its new campus	Roche announces the official inauguration of its Digital Centre of Excellence in Pune, India, marking a significant milestone in its history in India. This strategic presence in Pune reflects Roche's commitment to becoming a centre for digital talent and thought leadership.
5 th February	-	-	-
6 th February	Merck Foundation Marks World Cancer Day by Increasing the Limited Number of Oncologists in Africa Since 2012	Merck Foundation Marks World Cancer Day by Increasing the Limited Number of Oncologists in Africa Since 2012	Merck Foundation marks World Cancer Day together with Africa First Ladies and Ministries of Health through building cancer care capacity and increasing the limited number of oncologists in their countries by providing more than 140 Scholarships of

	ET Health World, February 06, 2024		one, two and three-years fellowship, diploma and Master Degree of oncology to African doctors from 28 Countries.
6 th February	Pfizer Ltd spurts 1.08%, gains for third straight session Business Standard, February 06, 2024	Pfizer Ltd spurts 1.08%, gains for third straight session	Pfizer Ltd is quoting at Rs 4710.35, up 1.08% on the day as on 12:49 IST on the NSE. The stock is up 22% in last one year as compared to a 23.46% gain in NIFTY and a 50.31% gain in the Nifty Pharma index. Pfizer Ltd is up for a third straight session in a row.
7 th February	Indian Cancer Society Launches Rise Against Cancer App BW Healthcare World, February 07, 2024	Indian Cancer Society Launches Rise Against Cancer App	Supported by Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) and powered by Roche, the app is available in English, Kannada, Hindi, Marathi, and Bengali. The Indian Cancer Society (ICS), India's largest anticancer NGO, has unveiled the Rise Against Cancer mobile app, designed to provide information, support, and community engagement in the battle against cancer.
7 th February	Novo Nordisk's parent invests in India's Manipal hospital chain Money Control, February 07, 2024	Novo Nordisk's parent invests in India's Manipal hospital chain	Novo Nordisk's parent invests in India's Manipal hospital chain Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, as it seeks to tap into growing market potential in Asia.
8 th February	Govt departments split as trade talks with European pharma firms hit last lap, patent key issue The Print, February 08, 2024	Govt departments split as trade talks with European pharma firms hit last lap, patent key issue	Representatives of the Organisation of Pharmaceutical Producers of India (OPPI), which represents multinational drugmakers, and the Indian Pharmaceutical Alliance (IPA), a network of research-based Indian pharma companies, were also invited for the meetings.
8 th February	Trade Talks: India's Pharmaceutical Landscape at a Crossroads BNN Breaking, February 08, 2024	Trade Talks: India's Pharmaceutical Landscape at a Crossroads	The pharmaceutical industry in India presents a mixed response. The Organisation of Pharmaceutical Producers of India (OPPI) supports the introduction of an RDP system, claiming it would foster innovation. However, the Indian Pharmaceutical Alliance (IPA) and Third World Network (TWN) present a contrasting view.
8 th February	Lupin Q3 results: Net profit surges to Rs 613 crore Business Today, February 08, 2024	Lupin Q3 results: Net profit surges to Rs 613 crore	This positive growth momentum coupled with cost optimization measures and operating leverage has helped us deliver solid performance." Sales in North America grew nearly 24% during the quarter, boosted by strong demand for Lupin's generic version of Boehringer Ingelheim's Spiriva Handihaler, an inhaler used for bronchial asthma.

8 th February	Riding on Novo Nordisk's semaglutide, India's weight-loss market triples in size in 2 years Money Control, February 08, 2024	Riding on Novo Nordisk's semaglutide, India's weight-loss market triples in size in 2 years	India's weight-loss market has almost tripled in size since January 2022, when Semaglutide, made by Danish drug maker Novo Nordisk, was launched in the market, highlighting a rising trend among Indians for weight-loss treatments. The weight-loss market today stands at Rs 474 crore against Rs 174 crore in January 2022, according to data compiled by research firm Pharmarack.
8 th February	Anti-obesity drugs drive revenue growth for Eli Lilly in Q4 2023 Business Today, February 08, 2024	Anti-obesity drugs drive revenue growth for Eli Lilly in Q4 2023	Verzenio is an Eli Lilly breast cancer drug used for hormone receptor positive, HER2negative advanced or metastatic breast cancer. Jardiance, developed by Boehringer Ingelheim and Eli Lilly, is a type 2 diabetes medication belonging to the SGLT2 inhibitor class, aiding in blood sugar control and reducing the risk of cardiovascular events in diabetic patients.
8 th February	MSD breaks ties with agency involved with Poonam Pandey The Economic Times, February 08, 2024	MSD breaks ties with agency involved with Poonam Pandey	MSD, the Indian affiliate of US drug giant Merck, has terminated its association with Schbang, the creative marketing solutions agency that was involved in the controversial publicity stunt by model and influencer Poonam Pandey in which she faked her own death.
9 th February	Govt departments split as trade talks with European pharma firms hit last lap, patent key issue Eflip, February 09, 2024	Govt departments split as trade talks with European pharma firms hit last lap, patent key issue	Representatives of the Organisation of Pharmaceutical Producers of India (OPPI), which represents multinational drugmakers, and the Indian Pharmaceutical Alliance (IPA), a network of research-based Indian pharma companies, were also invited for the meetings.
9 th February	Sanofi CHC India appoints Zepto's CHRO Roma Bindroo as People Director & Head of HR People Matters, February 09, 2024	Sanofi CHC India appoints Zepto's CHRO Roma Bindroo as People Director & Head of HR	Before her appointment, Roma served Zepto in the capacity of Chief Human Resources Officer. Prior to that, she worked with Tata Consumer Products as the Vice President of HR for NourishCo Beverages, Johnson & Johnson as the HR leader for Global Functions, and Mahindra and Mahindra as a Global HR Manager.
9 th February	Anti-obesity Drug Market Gaining Traction in India The Economic Times, February 09, 2024	Anti-obesity Drug Market Gaining Traction in India	India is seeing a significant spurt in the anti-obesity market after the launch of Novo Nordisk's Semaglutide (anti-obesity drug) in the year 2022. According to Pharma research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five years, the market has grown at 32% CAGR to 474 crore in January'24.
10 th February	JetSynthesys' Inclusional, National Commission for	JetSynthesys' Inclusional, National Commission for	Trade associations like NASSCOM (National Association of Software and Service

	Women (NCW) conduct a workshop for corporates on 'POSH beyond compliance' Passionate in Marketing, February 10, 2024	Women (NCW) conduct a workshop for corporates on 'POSH beyond compliance'	Companies), SEAP (Software Exporters' Association of Pune), HRIA (HR Infotech Association), HIA (Hinjewadi Industries Association), IACC (Indo-American Chambers of Commerce), OPPI (The Organisation of Pharmaceutical Producers of India), RAI (Retailers Association of India), IDMA (Indian Drug Manufacturers' Association), IPA (Indian Pharmaceutical Association), EEMA (Event and Entertainment Management Association), extended their whole-hearted support to this event by inviting their members for which Inclusional, Jet Social Impact extended their sincere thanks and gratitude.
10 th February	AstraZeneca Standalone December 2023 Net Sales at Rs 305.79 crore, up 22.41% YoY Money Control, February 10, 2024	AstraZeneca Standalone December 2023 Net Sales at Rs 305.79 crore, up 22.41% YoY	Net Sales at Rs 305.79 crore in December 2023 up 22.41% from Rs. 249.81 crore in December 2022. Quarterly Net Profit at Rs. 15.80 crore in December 2023 down 46.08% from Rs. 29.30 crore in December 2022. EBITDA stands at Rs. 24.71 crore in December 2023 down 43.56% from Rs. 43.78 crore in December 2022.
10 th February	AstraZeneca Pharma India Ltd leads losers in 'A' group Business Standard, February 10, 2024	AstraZeneca Pharma India Ltd leads losers in 'A' group	AstraZeneca Pharma India Ltd crashed 13.31% to Rs 5699.95 at 14:47 IST. The stock was the biggest loser in the BSE's 'A' group. On the BSE, 19664 shares were traded on the counter so far as against the average daily volumes of 1892 shares in the past one month.
10 th February	Anti-obesity drug market on steady growth path in India, shows data Business Standard, February 10, 2024	Anti-obesity drug market on steady growth path in India, shows data	Novo Nordisk is the innovator of the first two peptides, while Eli Lilly is the innovator of dulaglutide. Orlistat was developed by Roche. A person is considered obese if their Body Mass Index (BMI) is above 30. The BMI is defined as the body mass divided by the square of the body height
11 th February	-	-	-
12 th February	-	-	-
13 th February	BioAsia 2024: Driving Global Innovation in Life Sciences with Premier Industry Collaboration Deccan Chronicle, February 13, 2024	BioAsia 2024: Driving Global Innovation in Life Sciences with Premier Industry Collaboration	This will be first time, the event will have five industries joining together as Principal Industry Hosts including Novartis, Dr. Reddy's Laboratories, Bristol Meyers Squibb, Laurus Labs and Sai Lifesciences. This highlights the equal excitement and interest of Indian Multinationals and global multinationals alike to partner with the Government for BioAsia.
13 th February	GSK Pharma net profit down in Q3	GSK Pharma net profit down in Q3	GSK Pharma reported a decline in net profit by 72% to Rs 46 crore for the third quarter

	The Times of India, February 13, 2024		ended December 31, in the wake of regulatory price caps on some of its legacy brands. The drug firm had reported a net profit of Rs 165 crore in the year-ago period.
14 th February	-	-	-
15 th February	CDSCO gives nod to Boehringer Ingelheim's antidiabetic drug to treat chronic kidney disease in India The Financial Express, February 15, 2024	CDSCO gives nod to Boehringer Ingelheim's antidiabetic drug to treat chronic kidney disease in India	The Central Drugs Standard Control Organisation (CDSCO) has approved Boehringer Ingelheim's antidiabetic drug for the treatment of chronic kidney disease (CKD) in India. According to the company's statement, Jardiance (empagliflozin) 10mg tablets have been approved to reduce the risk of sustained decline in eGFR (only for patients with eGFR 30-90 ml/min/1.73m ²), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
16 th February	India rejects European FTA bloc's data exclusivity demand to protect generic drug firms interest The Economic Times, February 16, 2024	India rejects European FTA bloc's data exclusivity demand to protect generic drug firms interest	By gaining exclusive rights over this data, innovator companies can prevent their competitors from obtaining marketing licence for low-cost versions during the tenure of this exclusivity. Switzerland has some of the major pharma firms of the world and that include Novartis and Roche. Both these firms have a presence in India.
16 th February	Jardiance now approved in India for treatment of chronic kidney disease ET Health World, February 16, 2024	Jardiance now approved in India for treatment of chronic kidney disease	Chronic kidney disease is an important health issue, and there is a significant unmet need for therapies that slow disease progression and improve outcomes, said Gagandeep Singh Bedi, Managing Director, Boehringer Ingelheim India. We are very excited about the approval and the potential for empagliflozin to play an essential role in helping people living with kidney disease and their physicians.
16 th February	Johnson & Johnson Continues Sight for Kids Initiative to Bring Critical Eye Care to More Children in Underserved Communities in India The Print, February 16, 2024	Johnson & Johnson Continues Sight for Kids Initiative to Bring Critical Eye Care to More Children in Underserved Communities in India	Johnson & Johnson and Lions Clubs International Foundation (LCIF), a leader among international humanitarian volunteer organizations, continued their efforts to impact more than 7 million children in India over the next five years as part of Sight for Kids, a cofounded program to close the gap in access to eye care by providing comprehensive eye care services for children in low-income and underserved communities.
16 th February	Russia is close to creating cancer vaccines, claims Putin How will it impact	Russia is close to creating cancer vaccines, claims Putin 	Pharmaceutical companies Moderna and Merck & Co are developing an experimental cancer vaccine that a mid-stage study

	India's medical burden India Tv News, February 16, 2024	How will it impact India's medical burden	showed to cut the chance of recurrence or death from melanoma the most-deadly skin cancer by half after three years of treatment.
17 th February	-	-	-
18 th February	-	-	-
19 th February	-	-	-
20 th February	Novartis soars 11%; board to support parent firm explore strategic options Business Standard, February 20, 2024	Novartis soars 11%; board to support parent firm explore strategic options	Shares of Novartis India hit a multiyear high of Rs 1,148, as they rallied 11 per cent on the BSE in Monday's intraday deals after the parent firm announced its intention of a strategic review. In past three months, the stock of pharmaceutical company has zoomed 65 per cent. It had hit a record high of Rs 1,436.35 on December 6, 1999. Click here to follow our WhatsApp channel.
20 th February	AstraZeneca's DKD pipeline highlights potential to differentiate in kidney disease space The Financial Express, February 20, 2024	AstraZeneca's DKD pipeline highlights potential to differentiate in kidney disease space	In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the safety and efficacy of tozorakimab in subjects with DKD.
20 th February	Novartis India share price surges nearly 11% to hit a 52week high as Novartis AG announces sale plans for the co Live Mint, February 20, 2024	Novartis India share price surges nearly 11% to hit a 52week high as Novartis AG announces sale plans for the co	Novartis India share price surged nearly 11% to touch a 52-week high following the announcement on Friday of a strategic review of the company (Novartis India) by pharmaceutical giant Novartis AG. Novartis India share price today opened at an intraday high of 1,148 apiece on BSE.
20 th February	Dr Reddy's scales 52week high on buzz over plans to acquire Novartis India arm Money Control, February 20, 2024	Dr Reddy's scales 52week high on buzz over plans to acquire Novartis India arm	Shares of Dr Reddy's Laboratories rose over 2 percent and hit a 52week high of Rs 6,453.95 following a report by CNBCTV18 that the company is in the race to acquire Novartis AG's stake in Novartis India. The management of Dr Reddy's has also repeatedly hinted their interest in acquiring a domestic focused portfolio, in the recent earnings calls.
21 st February	Punters' Hopes of Delisting Gains Dashed as MNCs Opt for Stake Sales The Economic Times, February 21, 2024	Punters' Hopes of Delisting Gains Dashed as MNCs Opt for Stake Sales	A 4% stake sale would be valued at around 21,000 crore at the current market price. ITC is currently trading at 25 times while BAT is at 6 times. Novartis AG, which holds a 70.68% stake in Novartis India, announced this week that it is evaluating the possibility of selling its stake in the Indian firm.
21 st February	Novartis India Ltd leads losers in B group Business Standard, February 21, 2024	Novartis India Ltd leads losers in B group	Novartis India Ltd lost 7.64% to Rs 1104 at 14:32 IST. The stock was the biggest loser in the BSE's B group. On the BSE, 1.21 lakh shares were traded on the counter so far as

			against the average daily volumes of 62173 shares in the past one month.
21 st February	Pfizer Ltd up for fifth session Business Standard, February 21, 2024	Pfizer Ltd up for fifth session	Pfizer Ltd is quoting at Rs 4620.05, up 0.32% on the day as on 12:44 IST on the NSE. The stock is up 20.93% in last one year as compared to a 24.32% spurt in NIFTY and a 57.53% spurt in the Nifty Pharma. Pfizer Ltd is up for a fifth straight session in a row.
22 nd February	JB Chemicals eyes \$100 million revenue from contract manufacturing in 35 years CNBC TV18, February 22, 2024	JB Chemicals eyes \$100 million revenue from contract manufacturing in 35 years	964 crore (\$116 million). The acquisition will take effect from January 2027. JB Chemicals recently acquired around 15 ophthalmology drugs from the pharmaceutical giant Novartis for 964 crore (\$116 million). The acquisition will take effect from January 2027.
23 rd February	Approval on Pharma MNCs reducing India footprint? The Times of India, February 23, 2024	Approval on Pharma MNCs reducing India footprint?	Many have sold popular generic brands and even factories to big domestic firms, but experts say they're doing this to focus on core strengths, high-value products. Pharma MNCs in India have diverse growth strategies and business models. Anil Matai, director general of OPPI (Organisation of Pharmaceutical Producers of India), which represents pharma MNCs, says some have comprehensive portfolios of general medicines across therapy areas, and mega brands with a strong equity, others focus on a differentiated portfolio, while some MNCs focus on large innovator brands, deriving quick growth from co-marketing partnerships with Indian players.
23 rd February	Pfizer, Américas India Foundation's Project Parivartan demonstrates progress in addressing AMR in hospitals ET Health World, February 23, 2024	Pfizer, Américas India Foundation's Project Parivartan demonstrates progress in addressing AMR in hospitals	Pfizer and Américas India Foundation (AIF) today proudly announced success of Project Parivartan, with its 11 participating hospitals across 7 states scoring an average of 90 per cent across Infection Prevention and Control (IPC) and Antimicrobial Stewardship (AMS), in the National Accreditation Board for Hospitals & Healthcare Providers (NABH) audit.
23 rd February	India pharma companies develop versions of Wegovy to get in on weight-loss windfall The Economic Times, February 23, 2024	India pharma companies develop versions of Wegovy to get in on weight-loss windfall	Rival Eli Lilly likewise has been unable to meet demand for its weight-loss drugs Zepbound and Mounjaro Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026 The move by Indian drugmakers could go a long way toward improving global access to weight-loss drugs and make them far more affordable, analysts said

23 rd February	ORF, Gilead Sciences new report identifies how technology can transform health systems in emerging economies ET Health World, February 23, 2024	ORF, Gilead Sciences new report identifies how technology can transform health systems in emerging economies	A report launched by the Observer Research Foundation (ORF) and Gilead Sciences at the high-profile Raisina Dialogue in Delhi on Thursday informed that new technology and delivery models are making health more accessible pointing the way to a new era in which healthcare is both equitable and inclusive for all.
24 th February	Takeda oncology pipeline remains robust despite shift in focus from CART to allogeneic cell therapies, says GlobalData The Financial Express, February 24, 2024	Takeda oncology pipeline remains robust despite shift in focus from CART to allogeneic cell therapies, says GlobalData	Takeda has decided to discontinue the development programs of its four oncology assets Phase III asset modakafusp alfa (TAK573) and three Phase I chimeric antigen receptor (CART) assets: TAK102, TAK103 and TAK940as part of a plan to align its focus on advancing allogeneic cell therapies. Despite these adjustments, the Japan-based pharma major s oncology pipeline remains robust, says GlobalData, a data and analytics company.
24 th February	AstraZeneca Gets CDSCO Panel nod to study Anticancer Drug Datopotamab Deruxtecan and Durvalumab Medical Dialogues, February 24, 2024	AstraZeneca Gets CDSCO Panel nod to study Anticancer Drug Datopotamab Deruxtecan and Durvalumab	The drug major AstraZeneca has got approval from the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of the anticancer drug Datopotamab deruxtecan (DatoDXd, DS1062a) 100mg/vial and Durvalumab (MEDI4736) 500mg/vial (50mg/mL).
24 th February	Will the wave of restructuring help 7 MNC pharma stocks with upside potential of up to 14% The Economic Times, February 24, 2024	Will the wave of restructuring help 7 MNC pharma stocks with upside potential of up to 14%	In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level.
24 th February	Sanofi India board declares interim dividend of 50 per share CNBC TV18, February 24, 2024	Sanofi India board declares interim dividend of 50 per share	The Board has declared an Interim Dividend of 50 per equity share of the face value of, 10 each for the Financial Year ended 31st December 2023, to be paid to those members whose name appear on the register of members of the company on 7th March 2024 being the record date, Sanofi India said in a regulatory filing.
24 th February	ORF and Gilead Sciences launch report on how technology can transform health systems in emerging economies Express Healthcare, February 24, 2024	ORF and Gilead Sciences launch report on how technology can transform health systems in emerging economies	Health is vital to ending poverty in emerging economies. The good news, from a report launched by the Observer Research Foundation (ORF) and Gilead Sciences at the high-profile Raisina Dialogue in Delhi recently, is that new technology and delivery models are making health accessible to more people than ever.
25 th February	BioAsia 2024 to kickstart with an array of international	BioAsia 2024 to kickstart with an array of international eminent	The fourth panel discussion on Pharma Services: Navigating the path to global

	<p>eminent speakers and leaders from life sciences and healthcare sectors; Hon'ble Chief Minister of Telangana to inaugurate the event on February 27th at HICC Pune Prahar, February 25, 2024</p>	<p>speakers and leaders from life sciences and healthcare sectors; Hon'ble Chief Minister of Telangana to inaugurate the event on February 27th at HICC</p>	<p>eminence in the CRO and CDMO landscape will have Mr. Jonathan Hunt, CEO & Managing Director, Syngene; Mr. Manni Kantipudi, CEO, Aragen Lifesciences; Mr. Sauri Gudlavalleti, COO, Sai Lifesciences; Mr. Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services; Mr. Anil Matai, Director General, OPPI India; Mr. Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Ltd as the key speakers and the moderator will be Mr. Suresh Subramanian, Partner & National Life Sciences Leader, EY.</p>
25 th February	<p>Why are pharma MNCs reducing India footprint? The Times of India, February 25, 2024</p>	<p>Why are pharma MNCs reducing India footprint?</p>	<p>Anil Matai, director general of OPPI (Organisation of Pharmaceutical Producers of India), which represents pharma MNCs, says some have comprehensive portfolios of general medicines across therapy areas, and mega brands with a strong equity, others focus on a differentiated portfolio, while some MNCs focus on large innovator brands, deriving quick growth from co-marketing partnerships with Indian players.</p>
25 th February	<p>CDSCO Panel Grants Roche's Protocol Amendment Proposal For Anticancer Drug Giredestrant Medical Dialogues, February 25, 2024</p>	<p>CDSCO Panel Grants Roche's Protocol Amendment Proposal For Anticancer Drug Giredestrant</p>	<p>The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment of the drug major Roche s clinical study titled A study evaluating the efficacy and safety of adjuvant Giredestrant compared with Physician s choice endocrine monotherapy in participants with estrogen receptor positive, HER2 Negative early breast cancer.</p>
25 th February	<p>Sanofi India Q3 PAT rises 5% YoY to Rs 138 cr Business Standard, February 25, 2024</p>	<p>Sanofi India Q3 PAT rises 5% YoY to Rs 138 cr</p>	<p>Sanofi India reported 5.19% jump in net profit to Rs 137.7 crore in Q3 FY24 as compared with Rs 130.9 crore in Q3 FY23. In Q3 FY24, profit before tax fell 0.84% to Rs 188.8 crore as compared with Rs 190.4 crore in Q3 FY23.</p>
25 th February	<p>Company is giving dividend of Rs 50 on 1 share, record date declared Live Hindustan, February 25, 2024</p>	<p>Company is giving dividend of Rs 50 on 1 share, record date declared</p>	<p>There is good news for investors betting on dividend paying companies. Sanofi India has decided to give a dividend of Rs 50 on 1 share. The company has announced the record date for this dividend. In which more days are left now.</p>
26 th February	<p>CDSCO Panel Approves Roche's protocol amendment proposal for anticancer drug Atezoluzumab study</p>	<p>CDSCO Panel Approves Roche's protocol amendment proposal for anticancer drug Atezoluzumab study</p>	<p>A phase III randomised double-blind placebo controlled clinical trial to evaluate the efficacy and safety of adjuvant Atezoluzumab or placebo and Trastuzumab Emtansibe for HER2 Positive Breast Cancer</p>

	Medical Dialogues, February 26, 2024		at high risk of recurrence following preoperative therapy.
26 th February	Moderna, Pfizer, Oxford Vaccines Linked With Slight Increase In Heart, Brain Disorders: Study Pragativadi, February 26, 2024	Moderna, Pfizer, Oxford Vaccines Linked With Slight Increase In Heart, Brain Disorders: Study	Covid19 vaccines, including those from Moderna, Pfizer and Oxford, have been linked with a slight increase in heart, brain, and blood disorders, according to a new study. The Pfizer/BioNTech and Moderna Covid19 vaccines are mRNA vaccines, while the Oxford-AstraZeneca vaccine, the formula of which was replicated by the Serum Institute of India (SII) to manufacture Covishield, is an adenovirus vector vaccine.
26 th February	Revanth to inaugurate BioAsia 2024 at HICC on Feb. 27 Deccan Chronicle, February 26, 2024	Revanth to inaugurate BioAsia 2024 at HICC on Feb. 27	This will be the first time the event will have five industries joining as principal industry hosts including Novartis, Dr Reddy s Laboratories, Bristol Meyers Squibb, Laurus Labs, and Sai Life Sciences. In a media statement, Minister D. Sridhar Babu said, BioAsia 2024 exemplifies the power of government industry collaboration in driving innovation and shaping the future of the life sciences industry.
27 th February	BioAsia 2024 to kickstart with an array of international eminent speakers and leaders from life sciences and healthcare sectors Media Bulletins, February 27, 2024	BioAsia 2024 to kickstart with an array of international eminent speakers and leaders from life sciences and healthcare sectors	The fourth panel discussion on Pharma Services: Navigating the path to global eminence in the CRO and CDMO landscape will have Mr. Jonathan Hunt, CEO & Managing Director, Syngene; Mr. Manni Kantipudi, CEO, Aragen Lifesciences; Mr. Sauri Gudlavalleti, COO, Sai Lifesciences; Mr. Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services; Mr. Anil Matai, Director General, OPPI India; Mr. Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Ltd as the key speakers and the moderator will be Mr. Suresh Subramanian, Partner & National Life Sciences Leader, EY.
27 th February	Pfizer, Niper collaborate to support healthcare startups in India Business Standard, February 27, 2024	Pfizer, Niper collaborate to support healthcare startups in India	Pfizer on Monday announced a collaboration with the National Institute of Pharmaceutical Education & Research (Niper), Ahmedabad, through its INDovation programme. This partnership aims to incubate and support healthcare startups, providing funding of up to Rs 25 lakh to each selected startup along with incubation facilities at NIPER Ahmedabad.
27 th February	Sanofi India Standalone December 2023 Net Sales at Rs 693.90 crore, up 3.27% YoY	Sanofi India Standalone December 2023 Net Sales at Rs 693.90 crore, up 3.27% YoY	Sanofi India EPS has increased to Rs. 59.79 in December 2023 from Rs. 56.84 in December 2022. Sanofi India shares closed at 9,134.85 on February 23, 2024 (NSE) and

	Money Control, February 27, 2024		has given 26.86% returns over the last 6 months and 69.29% over the last 12 months.
27 th February	Bristol Myers Squibb opens innovation hub in Hyderabad The Economic Times, February 27, 2024	Bristol Myers Squibb opens innovation hub in Hyderabad	Bristol Myers Squibb (BMS), the US-based global drug maker on Monday announced the opening of a new innovation hub in Hyderabad. The state-of-the-art site will expand the company's global drug development and information technology and digital capabilities and is expected to house over 1,500 employees.
27 th February	Takeda injects hope: Dengue vaccine clinical trials set to begin in India Business Standard, February 27, 2024	Takeda injects hope: Dengue vaccine clinical trials set to begin in India	India may soon have access to the dengue vaccine Qdenga from Japan's Takeda Pharmaceutical Company, as the patient-focused, research and development (R&D)-driven global biopharmaceutical company has recently received a no-objection certificate from the Indian regulator to conduct local clinical trials, according to senior company executives.
27 th February	\$100-million facility of Bristol Myers Squibb opened in Hyderabad The Hindu, February 27, 2024	\$100-million facility of Bristol Myers Squibb opened in Hyderabad	A new facility of Bristol Myers Squibb was opened in Hyderabad on Monday. It is aimed at expanding the biopharmaceutical major's global drug development as well as IT and digital capabilities and is expected to seat over 1,500 employees.
28 th February	BioAsia 2024 to kickstart with an array of international eminent speakers and leaders from life sciences and healthcare sectors FM Live, February 28, 2024	BioAsia 2024 to kickstart with an array of international eminent speakers and leaders from life sciences and healthcare sectors	The fourth panel discussion on Pharma Services: Navigating the path to global eminence in the CRO and CDMO landscape will have Mr. Jonathan Hunt, CEO & Managing Director, Syngene; Mr. Manni Kantipudi, CEO, Aragen Lifesciences; Mr. Sauri Gudlavalleti, COO, Sai Lifesciences; Mr. Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services; Mr. Anil Matai, Director General, OPPI India; Mr. Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Ltd as the key speakers and the moderator will be Mr. Suresh Subramanian, Partner & National Life Sciences Leader, EY.
28 th February	Hyd's innovative ecosystem unlike anywhere else The Times of India, February 28, 2024	Hyd's innovative ecosystem unlike anywhere else	Pharma giant Bristol Myers Squibb s (BMS) CEO Chris Boerner is extremely bullish on Hyderabad, where the company is injecting \$100 million in what is poised to emerge as the company's largest site outside of the US for drug discovery, IT & digital innovation by the end of this year.
28 th February	Pfizer joins hands with NIPER Ahmedabad to support Healthcare Innovation in India	Pfizer joins hands with NIPER Ahmedabad to support Healthcare Innovation in India	Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups. Program will provide funding up to Rs. 25 lacs to each selected startup and

	The Week, February 28, 2024		incubation at the National Institute of Pharmaceuticals Education and Research (NIPER) Ahmedabad.
28 th February	Pfizer Ltd down for fifth straight session Business Standard, February 28, 2024	Pfizer Ltd down for fifth straight session	Pfizer Ltd is quoting at Rs 4359.35, down 0.93% on the day as on 13:19 IST on the NSE. The stock gained for a third straight session today in last one year as compared to a 28.37% up 0.38% in NIFTY and a 61.97% up 30.9% in the Nifty Pharma index.
28 th February	Roche launches Ocrevus in India MINT, February 28, 2024	Roche launches Ocrevus in India	Roche Pharma India, a subsidiary of Swiss pharmaceutical giant Roche, has launched monoclonal antibody drug Ocrevus (ocrelizumab) in India for the treatment of multiple sclerosis. The company said Ocrevus is the first disease-modifying therapy (DMT) for both relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) and targets 150,000-200,000 patients diagnosed with multiple sclerosis in India.
28 th February	India to be No. 2 R&D site by 2025: Bristol Myers CEO The Financial Express, February 28, 2024	India to be No. 2 R&D site by 2025: Bristol Myers CEO	US Drugmaker Bristol Myers Squibb aims to expand its R&D presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the US by 2025, CEO Christopher Boerner said on Tuesday.
28 th February	Takeda in talks to launch dengue vaccine in India The Financial Express, February 28, 2024	Takeda in talks to launch dengue vaccine in India	Japan's Takeda Pharmaceutical is in talks with Indian regulators to make its dengue vaccine available in the country, the drugmaker's global head of vaccines, Gary Dubin, said on Tuesday.
28 th February	Roche Launches Drug for Multiple Sclerosis The Economic Times, February 28, 2024	Roche Launches Drug for Multiple Sclerosis	Roche Pharma India on Tuesday launched a drug for the treatment of multiple sclerosis (MS). The company has introduced Ocrevus (Ocrelizumab), which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis and Primary Progressive Multiple Sclerosis.
29 th February	India gets breakthrough multiple sclerosis drug, but could be unaffordable to many at Rs 10+ lakh a yr The Print, February 29, 2024	India gets breakthrough multiple sclerosis drug, but could be unaffordable to many at Rs 10+ lakh a yr	Swiss drugmaker Roche Pharma Tuesday announced the launch of Ocrelizumab, sold under the brand name Ocrevus, claiming that it can effectively help manage MS a debilitating neurological condition and impede disability progression.
29 th February	Roche launches Ocrevus for multiple sclerosis treatment in India PharmaBiz, February 29, 2024	Roche launches Ocrevus for multiple sclerosis treatment in India	Roche Pharma India today announced the launch of its blockbuster breakthrough drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of numerous patients grappling with this debilitating disease in India.

29 th February	Pfizer, NIPER Ahmedabad join hands to support healthcare innovation in India Medical Dialogues, February 29, 2024	Pfizer, NIPER Ahmedabad join hands to support healthcare innovation in India	This partnership expands on the successful Pfizer INdovation initiative, through which 34 startups in India have already been supported through funding and incubation to bring their breakthroughs to market. Through this partnership with NIPER Ahmedabad, this initiative will follow a cohort-based approach with the aim of selecting 6 innovators panIndia, that will be incubated at NIPER Ahmedabad.
29 th February	Bristol Myers Squibb opens new site in Hyderabad; To expand company s global drug development The Financial Express, February 29, 2024	Bristol Myers Squibb opens new site in Hyderabad; To expand company s global drug development	Bristol Myers Squibb on Tuesday announced the official opening of a new facility in Hyderabad. The state-of-the-art site will expand the company s global drug development and IT & digital capabilities and is expected to be home to over 1,500 employees.
29 th February	Takeda and Biological E partner to boost dengue vaccine production in India Business Today, February 29, 2024	Takeda and Biological E partner to boost dengue vaccine production in India	Japanese multinational pharmaceutical company Takeda has inked a strategic partnership with Indian vaccine and biologic company Biological E. Limited, to boost the manufacture of Takeda s dengue vaccine, TAK003. The partnership is expected to significantly enhance vaccine manufacturing capabilities, with Biological E scaling up its production capacity to potentially reach 50 million doses annually.
29 th February	Notable gaps in understanding shingles risk among individuals above 50 years: GSK survey ET Health World, February 29, 2024	Notable gaps in understanding shingles risk among individuals above 50 years: GSK survey	GlaxoSmithKline Pharmaceutical Ltd released new data from a globally commissioned survey funded by them. The survey finds notable gaps in understanding of shingles risk among individuals aged above 50 years, a group that is most susceptible to the disease.
29 th February	Eli Lilly CEO David Ricks says its obesity drug could enter India as early as 2025 Money Control, February 29, 2024	Eli Lilly CEO David Ricks says its obesity drug could enter India as early as 2025	Eli Lilly CEO David Ricks says its obesity drug could enter India as early as 2025 Eli Lilly expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday.
29 th February	Eli Lilly may launch obesity drug in India next year: CEO Business Standard, February 29, 2024	Eli Lilly may launch obesity drug in India next year: CEO	US drugmaker Eli Lilly expects to launch Mounjaro, its diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, Chief Executive Officer David Ricks said on Wednesday.